哌拉西林他唑巴坦钠联合阿米卡星治疗老年重症肺炎的效果研究

Study on the Effect of Piperacillin-tazobactam Sodium Combined with Amikacin in the Treatment of Elderly Patients with Severe Pneumonia

目的 探讨哌拉西林他唑巴坦钠联合阿米卡星治疗老年重症肺炎的效果。方法 方便选择2018年9月—2021年8月胶州市中医医院治疗的102例重症肺炎老年患者为研究对象,分组方法为随机数表法,每组51例。两组均行常规对症治疗,对照组应用哌拉西林他唑巴坦钠,研究组在此基础上联合阿米卡星。比较两组临床疗效、治疗前后的肺部感染评分(CPIS)、炎症指标[白细胞计数(WBC)、降钙素原(PCT)、C反应蛋白(CRP)],以及不良反应情况。结果 研究组总有效率为96.08%高于对照组的80.39%,差异有统计学意义(χ^(2)=6.044,P<0.05)。治疗14 d后,研究组肺炎感染评分(5.26±0.52)分低于对照组的(7.20±0.80)分,差异有统计学意义(t=14.520,P<0.01)。治疗14 d后,研究组WBC、PCT、CRP均低于对照组,差异有统计学意义(P<0.01)。两组患者的不良反应发生率对比差异无统计学意义(P>0.05)。结论 老年重症肺炎患者应用哌拉西林他唑巴坦钠联合阿米卡星治疗效果确切,能有效抑制炎症反应,且安全性尚可。

Objective To investigate the effect of piperacillin-tazobactam sodium combined with amikacin in the treat⁃ment of elderly patients with severe pneumonia.Methods 102 elderly patients with severe pneumonia treated at Jiao⁃zhou Traditional Chinese Medicine Hospital from September 2018 to August 2021 were conveniently selected as the research subjects.The grouping method was random number table method,with 51 patients in each group.Both groups received routine symptomatic treatment,while the control group received piperacillin tazobactam sodium,while the study group received amikacin in combination on this basis.The clinical efficacy,pulmonary infection score(CPIS),inflammation indicators[white blood cell count(WBC),Calcitonin(PCT),C-reactive protein(CRP)],and ad⁃verse reactions were compared between the two groups before and after treatment.Results The total effective rate of the study group was 96.08%,which was higher than 80.39%of the control group,the difference was statistically sig⁃nificant(χ2=6.044,P<0.05).After 14 days of treatment,the pneumonia infection score of the study group(5.26±0.52)points was lower than that of the control group(7.20±0.80)points,the difference was statistically significant(t=14.520,P<0.01).After 14 days of treatment,the WBC,PCT,and CRP levels in the study group were lower than those in the control group,the difference was statistically significant(P<0.01).There was no statistically significant difference in the incidence of adverse reactions between the two groups of patients(P>0.05).Conclusion The use of piperacillin tazobactam sodium combined with amikacin in the treatment of elderly patients with severe pneumonia has a definite effect,effectively suppresses inflammatory reactions,and the safety is still acceptable.